The Lancet· Heinz Wiendl, Robert Bermel, Laura Airas, Tanuja Chitnis, Jin Nakahara, Mitzi Williams, Monika Adamczyk-Sowa, Karolina Piasecka-Stryczynska, Ronald Zielman, Sinead Dunphy, Nicolas Panchaud, Min Cai, Jing Xi, Brett Loop, Wendy Su, Roman Willi, Xavier Montalban, REMODEL Investigators·· 7 hours agoScore72
[Articles] Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
In brief
In two randomised phase 3 trials, REMODEL-1 and REMODEL-2, remibrutinib was superior to teriflunomide in patients with relapsing multiple sclerosis and maintained a favourable safety profile. The findings support remibrutinib as a potential new oral treatment option for relapsing multiple sclerosis.
Source: The Lancet · thelancet.com